Plant-produced insulin enters a Phase I/II trial in the UK
This article was originally published in Scrip
Manufacturing medicines in plants has come a step closer with the start of a Phase I/II clinical trial ofSemBioSys Genetics' plant-derived insulin, SBS-1000, in healthy UK volunteers. SBS-1000 is the largest-volume biopharmaceutical ever produced in plants, the company says. Results of the study are expected next year.